title: Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1.
abstract: Various tumour markers have been evaluated in malignant pleural effusions, but not CD66c. This study evaluated the diagnostic ability of CD66c in lung adenocarcinoma-associated malignant pleural effusions (LA-MPEs) and compared it with other known tumour markers. Forty-seven cases of LA-MPE and 52 cases of benign pleural effusions were collected. The levels of CD66c, CEA, CA 19-9, and CYFRA 21-1 were measured by enzyme immunoassay. The expression of CD66c, CEA, and CA 19-9 in cell blocks was measured by immunocytochemistry. CEA had the best diagnostic values, with a sensitivity of 87.2% and specificity of 92.3%. Both CD66c and CA 19-9 showed the highest specificity of 98.1%, with sensitivities of 63.8% and 55.3%, respectively. CYFRA 21-1 had a sensitivity of 83.0% and specificity of 76.9%. CEA combined with CA 19-9 reached a sensitivity of 91.5% and a specificity of 98.1%. The sensitivities of immunocytochemical staining for CD66c, CEA, and CA 19-9 were 72.5%, 75%, and 40%, respectively. CD66c showed a diagnostic performance comparable to CYFRA 21-1 and CA 19-9 by enzyme immunoassay. Immunocytochemical study showed that CD66c and CEA were more sensitive than CA19-9. Both studies support CD66c as a potential tumour marker to differentiate LA-MPE from benign effusions.
authors.affiliation: 1Departments of Pathology 2Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Korea.
authors.forename: Seung-Myoung
authors.initials: SM
authors.lastname: Son
authors.forename: Hye-Suk
authors.initials: HS
authors.lastname: Han
authors.forename: Jin Young
authors.initials: JY
authors.lastname: An
authors.forename: Kang Hyeon
authors.initials: KH
authors.lastname: Choe
authors.forename: Ki Man
authors.initials: KM
authors.lastname: Lee
authors.forename: Ki Hyeong
authors.initials: KH
authors.lastname: Lee
authors.forename: So-Seul
authors.initials: SS
authors.lastname: Kim
authors.forename: Yong-Moon
authors.initials: YM
authors.lastname: Lee
authors.forename: Ho-Chang
authors.initials: HC
authors.lastname: Lee
authors.forename: Hyung Geun
authors.initials: HG
authors.lastname: Song
authors.forename: Ok-Jun
authors.initials: OJ
authors.lastname: Lee
mesh_terms: D000230:Adenocarcinoma / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism; D018395:CA-19-9 Antigen / Q000378:metabolism*; D002272:Carcinoembryonic Antigen / Q000378:metabolism*; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D005260:Female; D006801:Humans; D053539:Keratin-19 / Q000378:metabolism*; D008175:Lung Neoplasms / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016066:Pleural Effusion, Malignant / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism; D012680:Sensitivity and Specificity; D055815:Young Adult
chemical_list: D015703:Antigens, CD; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; C069847:CD66 antigens; D002272:Carcinoembryonic Antigen; D015815:Cell Adhesion Molecules; D053539:Keratin-19; C102012:antigen CYFRA21.1